	US 12,465,620 B2
	Method of treating aging frailty in subjects with inflammaging using human mesenchymal stem cells
Joshua M. Hare, Miami, FL (US); and Ana Marie Landin, Miami, FL (US)
Assigned to Longeveron Inc., Miami, FL (US)
Appl. No. 16/348,756
Filed by Longeveron Inc., Miami, FL (US)
PCT Filed Nov. 10, 2017, PCT No. PCT/US2017/061031 § 371(c)(1), (2) Date May 9, 2019, PCT Pub. No. WO2018/089752, PCT Pub. Date May 17, 2018.
Claims priority of provisional application 62/421,048, filed on Nov. 11, 2016.
Prior Publication US 2019/0290698 A1, Sep. 26, 2019
Int. Cl. A61K 35/28 (2015.01); A61P 9/00 (2006.01); A61P 39/00 (2006.01)

CPC A61K 35/28 (2013.01) [A61P 9/00 (2018.01); A61P 39/00 (2018.01); G01N 2500/00 (2013.01)]

8 Claims

1. A method of treating symptoms of aging frailty in a human subject, wherein the subject exhibits inflammaging; the method comprising:

(a) administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof; and

(b) decreasing the number of exhausted B cells (CD19⁺, CD27⁻, IgD⁻) in a sample of the subject's serum by at least 10% as compared to the number of exhausted B cells in a sample of the subject's serum prior to administration of said population of isolated allogeneic human mesenchymal stem cells, thereby treating said symptoms of aging frailty.